 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||
3 June 2008 | Volume 148 Issue 11
Background: Data on the association between subclinical thyroid dysfunction and coronary heart disease (CHD) and mortality are conflicting
Purpose: To summarize prospective evidence about the relationship between subclinical thyroid dysfunction and CHD and mortality.
Data Sources: MEDLINE (1950 to January 2008) without language restrictions and reference lists of retrieved articles were searched.
Study Selection: Two reviewers screened and selected cohort studies that measured thyroid function and then followed persons prospectively to assess CHD or mortality.
Data Extraction: By using a standardized protocol and forms, 2 reviewers independently abstracted and assessed studies.
Data Synthesis: Ten of 12 identified studies involved population-based cohorts that included 14 449 participants. All 10 population-based cohort studies examined risks associated with subclinical hypothyroidism (2134 CHD events and 2822 deaths), whereas only 5 examined risks associated with subclinical hyperthyroidism (1392 CHD events and 1993 deaths). In a random-effects model, the relative risk (RR) for subclinical hypothyroidism for CHD was 1.20 (95% CI, 0.97 to 1.49; P for heterogeneity = 0.14; I2 = 33.4%). Risk estimates were lower when higher-quality studies were pooled (RR, 1.02 to 1.08) and were higher among participants younger than 65 years (RR, 1.51 [CI, 1.09 to 2.09] for studies with mean participant age <65 years and 1.05 [CI, 0.90 to 1.22] for studies with mean participant age
Limitations: Individual studies adjusted for different potential confounders, and 1 study provided only unadjusted data. Publication bias or selective reporting of outcomes could not be excluded.
Conclusion: Subclinical hypothyroidism and hyperthyroidism may be associated with a modest increased risk for CHD and mortality, with lower risk estimates when pooling higher-quality studies and larger CIs for subclinical hyperthyroidism.
Author and Article Information
From University of Lausanne, Lausanne, Switzerland; University of California, San Francisco, San Francisco, California; and Leiden University Medical Center, Leiden, the Netherlands.
Acknowledgment: The authors thank Professor Jayne A. Franklyn (University of Birmingham, Birmingham, United Kingdom), Professor Anne R. Cappola (University of Pennsylvania, Philadelphia, Pennsylvania), Dr. Alice M. Arnold (University of Washington, Seattle, Washington), Dr. Patrick Maisonneuve (European Institute of Oncology, Milan, Italy), Dr. Mark Vanderpump (Royal Free Hampstead NHS Trust, Hampstead, United Kingdom), Professor Mike Tunbridge (Oxford Radcliffe Hospitals, Oxford, United Kingdom), Dr. Iervasi (Clinical Physiology Institute, Pisa, Italy) and Dr. Hak (Erasmus MC University Medical Center, Rotterdam, the Netherlands) for their assistance and for supplying additional data from their studies.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Nicolas Rodondi, MD, MAS, Department of Ambulatory Care and Community Medicine, University of Lausanne, Bugnon 44, 1011 Lausanne, Switzerland; e-mail, nicolas.rodondi{at}hospvd.ch.
Current Author Addresses: Drs. Ochs, Nanchen, Cornuz, and Rodondi: Department of Ambulatory Care and Community Medicine, University of Lausanne, Bugnon 44, 1011 Lausanne, Switzerland.
Dr. Auer: Department of Medicine, University of Lausanne, Bugnon 46, 1011 Lausanne, Switzerland.
Dr. Bauer: University of California, San Francisco, 185 Berry Street, Suite 5700, San Francisco, CA 94107.
Dr. Gussekloo: Department of Public Health and Primary Care, Leiden University Medical Center, V06-P, Postbus 9600, 2300 RC Leiden, the Netherlands. REVIEW
Meta-analysis: Subclinical Thyroid Dysfunction and the Risk for Coronary Heart Disease and Mortality
65 years). The RR was 1.18 (CI, 0.98 to 1.42) for cardiovascular mortality and 1.12 (CI, 0.99 to 1.26) for total mortality. For subclinical hyperthyroidism, the RR was 1.21 (CI, 0.88 to 1.68) for CHD, 1.19 (CI, 0.81 to 1.76) for cardiovascular mortality, and 1.12 (CI, 0.89 to 1.42) for total mortality (P for heterogeneity >0.50; I2 = 0% for all studies).
This article has been cited by other articles:
|
|
 |
|
  G. W. Neuberg, K. E. Stephenson, D. A. Sears, and R. J. McConnell Internet-Enabled Thyroid Hormone Abuse Ann Intern Med, January 6, 2009; 150(1): 60 - 61. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Auer and N. Rodondi Thyrotropin Levels and Coronary Heart Disease Mortality Arch Intern Med, December 8, 2008; 168(22): 2498 - 2499. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Vaidya and S. H S Pearce Management of hypothyroidism in adults BMJ, July 28, 2008; 337(jul28_1): a801 - a801. [Full Text]
|
|
|
|
|
|
All you need to read in the other general journals BMJ, June 7, 2008; 336(7656): 1271 - 1272. [Full Text] [PDF]
|
|
|
|
|
|
P. W. Ladenson Cardiovascular Consequences of Subclinical Thyroid Dysfunction: More Smoke but No Fire Ann Intern Med, June 3, 2008; 148(11): 880 - 881. [Full Text] [PDF]
|
|
Read all Rapid Responses
Article
